IV Contrast-Enhanced Cone Beam Computed Tomography (CBCT) in Radiotherapy
NCT04199754 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 6
Last updated 2024-05-31
Summary
The purpose of this study is to find out if giving intravenous (IV) contrast (a liquid that helps with the visibility of organs and blood vessels that is given through the vein with the use of a hollow needle) during a Cone Beam Computed Tomography (CBCT- a type of computerized X-ray) can help people who have image guided radiation therapy (IGRT) for the treatment of abdominal and pelvic tumors.
Conditions
- Pelvic Cancer
- Abdominal Cancer
Interventions
- DRUG
-
Omnipaque 300mg/mL Solution for Injection
Prior to the contrast enhanced Cone Beam CT, 100mL of Omnipaque will be administered by IV at a rate of 2mL per second, followed by administration of 50mL of 0.9% saline.
- RADIATION
-
Cone Beam CT
60 seconds after contrast administration, a Cone Beam CT will be performed.
- RADIATION
-
Radiation Therapy
Standard of Care Radiation Therapy will be administered, dosage depends on the type of tumor being treated.
- DRUG
-
0.9% Saline
50 ML of 0.9% Saline will be administered immediately after Omnipaque administration
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
David Horowitz, MD · Assistant Professor of Radiation Oncology at Columbia University Medical Center
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-10-01
- Primary Completion
- 2021-05-28
- Completion
- 2021-05-28
- FDA Drug
- Yes
- FDA Device
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Evaluation of a Cone-beam CT Scanner for Image Guided Radiotherapy
NCT05524454 ·Status: COMPLETED ·Phase: NA
-
Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET)
NCT01308905 ·Status: UNKNOWN ·Phase: NA
-
Helical CT, PET/CT, MRI, and CBCT Alone or in Combination in Predicting Jaw Invasion in Patients With Oral Cancer
NCT03053960 ·Status: TERMINATED
-
Methionine PET/CT Studies In Patients With Cancer
NCT00840047 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma
NCT02043899 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors
NCT01176500 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy
NCT03039413 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study
NCT01266096 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging
NCT04514692 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
11C Topotecan PET Imaging
NCT00253461 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm
NCT03453489 ·Status: COMPLETED ·Phase: PHASE2
-
Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors
NCT00588276 ·Status: COMPLETED ·Phase: PHASE1
-
A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG
NCT05160480 ·Status: ENROLLING_BY_INVITATION
-
A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent
NCT05111509 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Detection of Acid Sphingomyelinase/Ceramide Pathway Activation in Radiotherapy Patients Using Intravoxel Incoherent Motion (IVIM) Diffusion-weighted Magnetic Resonance Imaging and Serum Biomarkers
NCT02465723 ·Status: WITHDRAWN ·Phase: NA
-
Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT
NCT03846167 ·Status: ACTIVE_NOT_RECRUITING
-
124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study
NCT01583842 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Assessing 11C-Choline (11C-CH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas
NCT02849171 ·Status: COMPLETED ·Phase: NA
-
A Pilot Study For Patients Receiving Radiation Therapy for Liver Cancer
NCT06144827 ·Status: WITHDRAWN ·Phase: NA
-
Dual Energy Computed Tomography (CT) in Finding Bone Metastases in Patients With Cancer
NCT02354326 ·Status: TERMINATED
-
64Cu-DOTA Pembrolizumab for Imaging Metastatic Solid Tumors in Patients Receiving Stereotactic Body Radiation
NCT05728372 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors
NCT04260256 ·Status: TERMINATED ·Phase: PHASE2
-
PET Imaging of Subjects Using 124I-PU-AD
NCT03371420 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Expanded Access [11C] Methionine PET Imaging
NCT05511714 ·Status: AVAILABLE
-
A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors
NCT03057509 ·Status: WITHDRAWN ·Phase: PHASE1